icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs
 
 
  - propensity score-matched analysis of a prospective database -
 
AASLD: The incidence of hepatocellular carcinoma is not increased after DAA therapy - (11/13/17)
 
AASLD: Low Rates of De Novo or Recurrent Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals (DAAs): A Single-Center Experience - (11/16/17)
 
Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
 
Mina Nakagawa1)2)
Yasuhiro Asahina1)3) ,Hiroko Nagata1) and Mamoru Watanabe1)
1) Department of Gastroenterology and Hepatology
2) Institute of Education
3) Department of Liver Disease Control
Tokyo Medical and Dental University, Tokyo, Japan

1117171

1117172

1117173

1117174

1117175

1117176

1117177

1117178

1117179

11171710

11171711